Improved anti-breast cancer activity through structural modification of fused pyran derivatives and mechanistic investigations

Research Overview

This medicinal-chemistry study synthesized a series of novel fused pyran derivatives and evaluated their anticancer activity against three human cancer lines: MCF7 breast, A549 lung, and HCT116 colorectal carcinoma.

Structural modification of the pyran scaffold improved potency against breast cancer cells in particular. Derivatives 8a and 8b emerged as the most promising compounds, and the authors propose them as candidates for further preclinical development as breast cancer therapeutics.